SCHEMBL21552200

SCHEMBL21552200

CN(CCCS(=O)(=O)c1cccc(Br)c1)C(=O)O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.46
ALDH1A1 P00352 2/20 0.46
MAPT P10636 1/20 0.46
ATM Q13315 1/20 0.43
KDM4E B2RXH2 1/20 0.42
LMNA P02545 1/20 0.42
MEN1 O00255 1/20 0.39
HTT P42858 1/20 0.39
HDAC1 Q13547 2/20 0.39
HDAC8 Q9BY41 2/20 0.39
HSD11B1 P28845 1/20 0.39
HDAC3 O15379 1/20 0.39
HDAC4 P56524 1/20 0.39
HDAC7 Q8WUI4 1/20 0.39
HDAC2 Q92769 1/20 0.39
HDAC10 Q969S8 1/20 0.39
HDAC11 Q96DB2 1/20 0.39
HDAC6 Q9UBN7 1/20 0.39
HDAC9 Q9UKV0 1/20 0.39
HDAC5 Q9UQL6 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2552754 0.84 ALDH1A1 (0.48) KMT2AALDH1A1MAPTATMKDM4E
SCHEMBL24591935 0.83 KMT2A (0.39) KMT2AALDH1A1MAPTATMKDM4E
SCHEMBL29647929 0.83 KMT2A (0.39) KMT2AALDH1A1MAPTATMKDM4E
SCHEMBL17364184 0.79 ATM (0.45) KMT2AALDH1A1ATMMEN1HDAC1
SCHEMBL21872095 0.79 ATM (0.58) KMT2AALDH1A1ATMLMNAMEN1
SCHEMBL21552179 0.78 LIPG (0.42) KMT2AALDH1A1KDM4EMEN1HDAC1
SCHEMBL1710715 0.76 ATM (0.41) ALDH1A1ATM
SCHEMBL1369364 0.76 CA2 (0.50) ATMHDAC1HDAC8HSD11B1HDAC3
SCHEMBL1369921 0.76 CA2 (0.47) ATMHSD11B1EGFRERBB2BRD4
SCHEMBL21872042 0.75 ATM (0.61) KMT2AALDH1A1ATMKDM4EMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230079407-A1 ANTI-MSR1 ANTIBODIES AND METHODS OF USE THEREOF REGENERON PHARMACEUTICALS, INC. 2023-03-16 US disclosed
US-11377502-B2 Anti-MSR1 antibodies and methods of use thereof REGENERON PHARMACEUTICALS, INC. (US) 2022-07-05 US disclosed
EP-3790899-A1 ANTI-MSR1 ANTIBODIES AND METHODS OF USE THEREOF REGENERON PHARMACEUTICALS, INC. (US) 2021-03-17 EP disclosed
WO-2019217591-A1 ANTI-MSR1 ANTIBODIES AND METHODS OF USE THEREOF REGENERON PHARMACEUTICALS, INC. (US) 2019-11-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230079407-A1 ANTI-MSR1 ANTIBODIES AND METHODS OF USE THEREOF CD47, MSR1, LDLR KMT2A 710/4885ALDH1A1 3728/4885MAPT 4571/4885
US-11377502-B2 Anti-MSR1 antibodies and methods of use thereof CD47, MSR1, LDLR KMT2A 710/4885ALDH1A1 3728/4885MAPT 4571/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.